Abstract Increasingly, our approach to cerebrovascular disease has become blurred by evidence published in literature often without careful consideration of what this evidence implies for specific patients at hand. In this essay, we analyze key contextual issues in cerebrovascular small vessel disease, in an attempt to highlight the symbolic gap that exists between research and clinical practice, a recurring theme in medicine. We highlight the importance of considering context when using data from epidemiologic, neuroimaging, and biomarker studies in determining relevance to the patient at hand. We argue, that while biomarkers and neuroimaging may eventually serve to help to identify individuals with specific cerebrovascular diseases, we must always continue to understand patients in a specific clinical context. These reflections are particularly relevant when considering cerebral microbleeds-a key marker of cerebrovascular small vessel disease whose detection often raises thorny clinical dilemmas.
Over the last several decades, significant advances in epidemiology have considerably improved our ability to assess risk for a wide range of diseases. 1 For example, in individuals with defined cardiovascular disease, the risk of myocardial infarction and stroke can be estimated based on a variety of clinical risk factors and assessment tools. 2, 3 This has had tremendous influence on our recommendations for treatment and prevention and has contributed to an overall reduction in cardiovascular mortality. 4 However, despite the dramatic changes brought about by these advances, we remain at a loss as to know just what to say when a dinner party guest casually asks us how he can find out whether or not he will have a heart attack or stroke. While risk models derived from epidemiologic studies of cardiovascular disease may be able to accurately estimate his or her risk within a five-year, 10-year, or lifetime window, they cannot tell him whether that risk will actually be realized, or when. From the doctor's perspective, these risk models can predict how many patients will be seen with an acute MI or stroke on an average day, and the distribution of their risk factor profiles, but, the probabilistic information they provide does little to tell us which individuals in the community will come through the hospital's doors with a heart attack and just when they will arrive. 5, 6 Context is important in epidemiology. Epidemiologic studies focus on large populations to assess the probability of a given outcome over a defined interval in a specific context (e.g. 10-year risk in the general population, lifetime risk in individuals with a family history of the outcome, etc.). This risk probability is determined by the presence or absence or degree of a variety of defined risk factors (such as hypertension, smoking, or elevated cholesterol). In a similar way, clinical epidemiologic studies that start with patients who have experienced a given clinical event such as myocardial infarction or stroke and estimate risk of repeat event or new outcome going forward. These studies often include other features that essentially further define and refine context, such as age, gender, frailty, or particular risk factors like diabetes.
In recent years, rapid development of advanced imaging techniques has allowed physicians to obtain additional information in their patients who are at risk for a future clinical event such as myocardial infarction, stroke, or dementia. In the neuroimaging of cerebrovascular disease, markers for so-called silent microvascular brain injury such as cerebral microbleeds 7 or white matter hyperintensities 8 are two such examples. These neuroimaging biomarkers are clearly not risk factors in the epidemiologic sense-they are direct or indirect measures of underlying disease pathology rather than simply measure of disease risk in a probabilistic sense. Because these biomarkers resemble established diagnostic tests like blood cultures or biopsies rather than risk factors like hypertension or diabetes, clinicians tend to interpret them as they would a diagnostic test result. However, biomarkers are not diagnostic tests. Our use of them in a clinical setting requires a deeper understanding of context.
While we might tend to believe that seeing marker of small vessel disease on MRI is just as diagnostically useful as seeing malignant cells on a brain biopsy for glioma, these biomarkers behave less clearly than we generally tend to imagine or assume for several reasons. Like all diagnostic tests, there are issues surrounding detection technique parameters, diagnostic thresholds, and scaling, but we have not yet had enough experience with these brain MRI markers and their distribution in a variety of settings to reliably make these judgments broadly as one would for a biopsy. We have only begun to learn about such variation in neuroimaging data. 9, 10 A biopsy that is positive for brain cancer is just as valid in the asymptomatic population-based setting as it would be in the clinic. The same cannot yet be said, for example, of cerebral microbleeds, an emerging small vessel disease MRI marker. In addition, there remains a gap between what is seen on neuroimaging and what these findings correspond to pathologically.
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Finally and more critically, we do not yet fully understand the evolution of these biomarkers over time. Is an individual with one microbleed necessarily bound to develop many more? Will he experience a brain hemorrhage? Will he experience cognitive changes? Thus for the moment, these biomarkers fall somewhere between an epidemiologic risk factor and a diagnostic test. We therefore must use some of the same principles of context that we use in epidemiology to help us understand their clinical significance.
As physicians, we are limited by context. We can only evaluate and treat those who come through the doors of our hospital or our consultation room. A person becomes a patient only when he or she seeks medical consultation. The inherent structure of specialty medicine in particular entails people with symptoms coming to seek consultation from a physician who has specific expertise. These symptoms may or may not be associated with a specific disease or syndrome, but in the end, it is the physician's clinical judgment (based on expertise in the given specialty or subspecialty) that determines the symptoms' significance. If the symptoms are determined to represent a clinical diagnostic entity, then the physician draws on a set of specific clinical tools to assess the nature, severity, and prognosis of the given entity. These tools may range from the clinical examination (e.g. a test of cognitive function in a neurologist's office) to a biomarker evaluation obtained through advanced neuroimaging techniques (such as microbleeds on blood-sensitive gradient-echo MRI).
Clinical judgment is-and should be-strongly influenced by the context in which the test was performed-in other words, why a specific test was ordered affects the interpretation of the findings. Findings from some tests (such as malignant cells on a brain biopsy) are diagnostic no matter what the setting. However, many have different meanings depending on context. For example, a test may be ordered for the workup of symptoms for which the result will suggest that true disease is present (e.g. MRI of the brain in the workup of mild memory loss). If the MRI shows brain atrophy and silent stroke, this would confirm the clinician's hypothesis that the symptoms result from these pathologies. However, the specialty care setting in which a patient's symptoms are assessed likely affects what will be considered a true clinical diagnostic entity. If evaluation for memory loss is being performed in a highly specialized memory clinic, the interpretation of findings may differ to some extent from that of a general neurology clinic. And the same brain atrophy and silent stroke seen on a MRI of the brain ordered during a consultation for headache in would be considered entirely incidental findings. Similarly, tests performed as part of an evaluation for specific symptoms must be interpreted differently than those obtained for screening. For example, a borderline score on a Montreal Cognitive Assessment obtained as part of a memory evaluation would be more concerning than a borderline score obtained at an annual checkup in someone without symptoms (although in the latter case more detailed questioning about symptoms might be indicated). Meaning depends on context.
In cerebrovascular and cardiovascular disease, we are not yet able to easily identify incipient disease in individuals in the population without any symptoms International Journal of Stroke, 13 (1) who do not seek medical care. Although epidemiologic methods have allowed us to identify risk factors for diseases, they do not allow us to identify which individuals in the population will be affected, nor when they will be affected (if ever). 12 In other words, findings from such studies do not imply that everyone with elevated cholesterol is bound for a myocardial infarction, or even that patients with atrial fibrillation who are not anticoagulated are destined to develop an embolic stroke. As the impact of most epidemiologic risk factors in neurologic disease is limited, our predictive ability based solely on these variables is also limited. Even if all currently known risk factors for stroke were combined, our predictive ability in an individual patient would still not be much better than a coin toss. 13 This uncertainty (which applies similarly to the prediction of those who will not have a stroke) likely stems from a large number of unknown and unaccounted for variables, as well as poorly understood stochastic processes, recently investigated in conditions from cancer 14, 15 to cardiovascular disease. 16 While the epidemiological risk models are useful to support changes in lifestyle, prophylactic interventions, or health-related policy changes that would have a broader measureable impact at the societal level, these risk scores cannot be used to predict individual outcomes at specific times in the asymptomatic clinic patient or in the asymptomatic person in the population.
Increasingly, our approach to cerebrovascular disease has become blurred by evidence published in literature without careful consideration of what this evidence implies for specific patients at hand. We have found in our center that early trainees often only consider the main associations of these studies (e.g. ''is the p value less than 0.05?''), without considering whether that particular study's sample is relevant to a specific clinical situation. For example, populationbased studies may be cited on rounds in the Stroke Unit to give support for various clinical recommendations regarding an individual patient. However, this fails to consider one of the key tenets of epidemiologywhether the findings from a population-based study of healthy individuals can be extended to apply to a patient with a specific disease state-for instance multiple vascular risk factors, diabetes, and new onset stroke. We try to teach our residents that while it may not be necessary to know every methodological detail in a published study, it is critical to have a firm understanding of the cohort studied by always reading the first few lines of the methods section. Alternatively, and perhaps more commonly, some trainees may advocate aggressive treatment with statin medications for patients in the hospital with incidentally found silent stroke, citing trial evidence in patients with symptomatic stroke. 17, 18 Using statins to reduce the risk of silent stroke or to reduce the risk of first ever stroke ignores the lack of compelling evidence for such an intervention. As elsewhere in medicine, studies need to be put in context before deciding on clinical recommendations. However, our ability to make solid clinical recommendations based on such studies can still be limited even when one carefully considers these studies in context. While we have learned a tremendous amount of pathophysiology through translational studies and basic science research using data and samples from patients seen in tertiary care centers, it remains unclear if these findings are generalizable to patients seen in more typical specialty practice-much less to primary care patients or to healthy individuals in the general population. Such studies are conducted in a specific context, often with a precisely defined and highly selected group of patients. Even within these cohorts, sampling issues (e.g. population-based versus convenience sampling, and explicit and implicit inclusion/exclusion criteria) also determine how applicable findings will be to a particular clinical setting. 19 These contextual issues are particularly relevant when considering microbleeds-a key marker of small vessel disease in the brain. These T2* hypointense lesions seen on MRI have attracted considerable interest in cerebrovascular research in recent years. Studies of the implications and pathophysiology of cerebral microbleeds have shown that in cerebral amyloid angiopathy (CAA), lobar cerebral microbleeds are an important prognostic marker and appear to be associated with vascular amyloid deposition. 20 While microbleeds may point to the role of CAA in symptomatic intracerebral hemorrhage (ICH) in stroke populations and cognitive impairment in memory clinic populations, 21 these lesions have increasingly become an incidental finding on MRIs obtained for unrelated reasons or on MRIs in asymptomatic individuals in community studies. 22, 23 However, it is unclear if lobar cerebral microbleeds incidentally found in an MRI obtained in the evaluation of migraine headache or as part of a population-based research study carry the same implication for underlying CAA pathophysiology, much less for risk of brain hemorrhage or cognitive decline. 22 Despite early promising evidence, 22 it is yet unclear whether microbleeds found in this context have any clinical or prognostic significance for these outcomes, especially given the very small effect sizes. 22 The gap between the CAA disease population and healthy subjects with microbleeds is similar in some ways to the gap between Alzheimer's disease populations and asymptomatic individuals who are amyloid positive. 24 Again, context is important.
With respect to measurement uncertainty, in a more fundamental way it is still unclear whether the T2* hypointense lesion on MRI seen in patients with
International Journal of Stroke, 13 (1) brain hemorrhage represent the same underlying pathological lesion that is seen in patients with memory problems, let alone the same lesion that is seen in those with other or no indications for MRI. 11 Indeed, there is some evidence to suggest that even in established cases of CAA not all T2* hypointense lesions are the same pathologically. 25 This would imply that our use of the term ''microbleed'' may not always represent the small vessel microhemorrhage that these hypointense lesions invoke our minds' eye. However, there is currently no way to differentiate the underlying mechanisms or pathophysiological types of microbleeds on clinical or research neuroimaging.
More broadly, the results from neuroimaging of microbleeds are often used indiscriminately to make clinical judgments without careful consideration of these issues of context. Because of the nature of gradient echo-based techniques, cerebral microbleeds appear larger and thus more dramatic to us on MRI than on actual pathology. The potential importance of this particular ''visual bias'' in evaluating individuals with microbleeds should not be underestimated. Because visual perception is so critical to us as humans, it is possible that we assign microbleeds an importance greater than their true clinical significance (a heuristic that leads to bias 26 ). This example highlights how we often naturally tend to turn clinical observations directly into disease pathophysiology, often without the necessary biologic evidence to make such leaps. The philosopher of science Maurice Merleau-Ponty noted in Phenomenology of Perception that humans are ''condemned to meaning'' and that we are biologically wired to reduce the ubiquitous uncertainty in our world.
Overall, there is much that remains uncertain in microbleed and CAA research. It appears that patients with lobar microbleeds fulfilling the diagnosis of probable CAA vary considerably in their neuroimaging profile, have slightly differing underlying pathologies, 27 and may have different natural histories of disease. Patients with probable CAA seen in memory clinics are distinctly different from patients with probable CAA who present with ICH, and those who present with transient focal neurologic symptoms (TFNEs) may represent yet another group. 28 In light of these findings, a phenotype-based framework for CAA research may be useful going forward. 29 These proposed CAA phenotypes (e.g. ICH-related CAA, cognition-related CAA, non-ICH, TFNE-related CAA) would serve not only as labels but also serve to better describe the wide spectrum of the disease and the different aspects of the CAA-related small vessel pathology in each phenotype. 21 Knowing the inherent limitations of clinically based labels of disease in fully capturing underlying disease pathology, 30 further development of neuroimaging and blood biomarkers and their relationship to one another and to clinical disease and neuropathology will be important here.
Despite the uncertainties noted above, CAA is now readily identified using gradient-echo MRI sequences, while other forms of small vessel disease (SVD) are much less well characterized. 31 Unlike CAA, other SVDs suffer from a lack of clear identifying phenotypic labels that has slowed advancement in disease understanding and treatment. 31 Many of these lesions are virtually ubiquitous in late life and have been associated with cognitive decline in both clinical and population-based settings. 32, 33 They too likely represent a heterogenous group of pathologies that may have distinct natural histories. 31 Several international and US-based consortia have now been established to define biomarkers in SVD in an effort to facilitate evaluation of treatments for the disease in the coming years. 7, 34, 35 It will be thus critical to increase exchange between researchers and clinicians treating all SVDs to further advance our understanding of not only of microbleeds but of the role that each neuroimaging biomarker plays in these diseases.
These examples highlight the symbolic gap that exists between research and clinical practice in medicine. Despite this large gap, we continue to use information from both sides of the chasm to evaluate and treat our patients. While biomarkers and neuroimaging may eventually serve to help to identify individuals with specific neurologic disease, we must always continue to understand patients in a specific clinical context. The type of marker, its co-occurrence with other disease markers (e.g. microbleeds plus other SVD signatures, such as white matter hyperintensities, or lacunes, or brain atrophy), the patient's risk factor profile, the cross sectional and longitudinal relationship between the relevant pathologies and the clinical outcomes of interest also serve to define the clinical context. Context is thus critical-not only for us to better take care of our patients, but also to further advance our understanding of these common and debilitating diseases.
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